First Department of Respiratory Medicine, 'Sotiria' Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Biomolecules. 2023 Aug 23;13(9):1286. doi: 10.3390/biom13091286.
Recent advances in non-small cell lung cancer (NSCLC) biology and the discovery of novel therapeutic targets have led to the development of new pharmacological agents that may improve the clinical outcome of patients with NSCLC. The glucocorticoid receptor (GR) is an evolutionarily conserved protein belonging to the nuclear receptor superfamily of transcription factors and mediates the diverse actions of glucocorticoids in cells. Data suggest that the GR may play a relevant role in the molecular mechanisms of NSCLC tumorigenesis and malignant progression. Additionally, evidence indicates that glucocorticoids may affect the efficacy of standard treatment, including chemotherapy, immune checkpoint inhibitors, and targeted therapy. Furthermore, several findings show that GR expression may probably be associated with NSCLC patient survival. Finally, glucocorticoids may be used as therapeutic agents for the clinical management of NSCLC patients. Here, we briefly review the latest advances on the biological role of GR signaling in NSCLC and discuss the potential use of the GR as a prognostic and predictive biomarker. Importantly, we explore the therapeutic potential of glucocorticoids and the effect of adding such drugs to standard therapies for NSCLC.
近年来，非小细胞肺癌（NSCLC）生物学的进展和新治疗靶点的发现，导致了新的药理学药物的发展，这些药物可能改善 NSCLC 患者的临床结局。糖皮质激素受体（GR）是一种进化上保守的蛋白，属于核受体超家族转录因子，介导糖皮质激素在细胞中的多种作用。数据表明，GR 可能在 NSCLC 肿瘤发生和恶性进展的分子机制中发挥相关作用。此外，有证据表明，糖皮质激素可能影响标准治疗的疗效，包括化疗、免疫检查点抑制剂和靶向治疗。此外，有几项研究结果表明，GR 表达可能与 NSCLC 患者的生存有关。最后，糖皮质激素可用作 NSCLC 患者临床管理的治疗药物。在这里，我们简要回顾了 GR 信号在 NSCLC 中的最新生物学作用的研究进展，并讨论了将 GR 用作预后和预测生物标志物的潜在用途。重要的是，我们探讨了糖皮质激素的治疗潜力以及将此类药物添加到 NSCLC 标准治疗中的效果。
